A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor.

Blood
Tetsuro OritaMasayuki Tsuchiya

Abstract

Antibodies have brought valuable therapeutics in the clinical treatment of various diseases without serious adverse effects through their intrinsic features such as specific binding to the target antigen with high affinity, clinical safety as serum proteins, and long half-life. Agonist antibodies, furthermore, could be expected to maximize the value of therapeutic antibodies. Indeed, several IgG/IgM antibodies have been reported to induce cellular growth/differentiation and apoptosis. These agonist antibodies, however, should be further improved to exert more potent biologic activities and appropriate serum half-life depending upon the disease indications. Here, we report that IgG antibodies against the thrombopoietin receptor (Mpl), which have an absence or very weak agonist activity, can be engineered to be agonist minibodies, which include diabody or sc(Fv)2 as potent as natural ligand. Through this technological development, minibodies have been successfully constructed to bind and activate 2 types of dysfunctional mutant Mpls that cause congenital amegakaryocytic thrombocytopenia (CAMT). This drastic conversion of biologic activities by designing minibodies can be widely applicable to generate agonist minibodies for clinic...Continue Reading

References

Feb 1, 1994·Seminars in Immunology·A D Steinberg
Jul 1, 1995·Journal of Biochemistry·T KatoE Maeda
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·J G Drachman, K Kaushansky
Jul 10, 1998·Immunology Letters·M AbeY Masuho
Jan 29, 2000·Journal of Immunological Methods·P J Hudson, A A Kortt
Sep 6, 2000·British Journal of Haematology·S van den OudenrijnA E von dem Borne
Jun 6, 2003·Cytokine & Growth Factor Reviews·Steven R Wiley, Jeffrey A Winkles

❮ Previous
Next ❯

Citations

Jan 27, 2009·Current Gastroenterology Reports·Hans L TillmannJohn G McHutchison
Jul 31, 2009·Annual Review of Medicine·David J Kuter
Jul 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maoyong FuMadhuri Wadehra
Feb 10, 2007·Blood·David J Kuter
Oct 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kaori Fujimoto-Ouchi
Sep 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Shana FredericksonKatherine S Bowdish
Dec 22, 2007·Expert Review of Cardiovascular Therapy·Ara Metjian, Charles S Abrams
Feb 17, 2011·Expert Review of Hematology·Abdulgabar Salama
Sep 26, 2009·Clinical Lymphoma & Myeloma·David J Kuter
Jun 11, 2009·Journal of Immunological Methods·Kiyotaka NakanoKunihiro Hattori
Feb 19, 2009·Cytokine & Growth Factor Reviews·Michelle PeruginiRichard J D'Andrea
Jul 8, 2008·Drug Discovery Today·Karen PeetersKathleen Freson
Apr 9, 2008·Bioorganic & Medicinal Chemistry·Takeki SaitohFumio Sugawara
Jul 17, 2007·Seminars in Hematology·Stefan O Ciurea, Ronald Hoffman
Jul 28, 2009·Journal of Thrombosis and Haemostasis : JTH·Y Ikeda, Y Miyakawa
Apr 25, 2009·British Journal of Haematology·Matthias Ballmaier, Manuela Germeshausen
Jul 22, 2006·British Journal of Haematology·Varda R Deutsch, Aaron Tomer
Dec 24, 2005·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Tamara J StevensonShannon J Odelberg
Oct 13, 2005·Experimental Hematology·Francis Hérodin, Michel Drouet
Oct 7, 2011·Cytokine & Growth Factor Reviews·Anna TarasovaDavid Winkler
Sep 16, 2016·Frontiers in Bioengineering and Biotechnology·Vimal Kishor SinghRamesh Chandra
Dec 2, 2017·Nature Reviews. Drug Discovery·Paul J Carter, Greg A Lazar
Aug 25, 2020·Advanced Science·Pingdong TaoRichard A Lerner
Jul 5, 2019·Molecular Cancer Therapeutics·Tatsushi KodamaKoichi Akashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis